NCT04112368View on ClinicalTrials.gov

Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2024

Conditions
Suicidal Ideation
Interventions
DRUG

Estradiol Transdermal Patch 0.1 mg/24 hrs

Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation

DRUG

Oral Micronized Progesterone 200mg

100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation (200mg total per day)

DRUG

Inactive Clear Patch

Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation

DRUG

Placebo capsule

Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation

Trial Locations (1)

60612

University of Illinois Neuropsychiatric Institute, Chicago

All Listed Sponsors
lead

University of Illinois at Chicago

OTHER

NCT04112368 - Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach | Biotech Hunter | Biotech Hunter